APGE Apogee Therapeutics, Inc. Common Stock Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
11:13
Jul 14
Jul 14
Bearish/do-not-buy APGE view without explicit short.
Avoid APGE: author criticizes late me-too commercial case and says success depends on failure to adopt efficacious biosimilars; bearish/do-not-buy view without explicit short.
MED
01:49
Jul 08
Jul 08
Referenced as prior AbbVie acquisition whose merger docs reveal AbbVie's BD cadence and appetite for back-to-back deals.
LOW
23:56
Jul 02
Jul 02
The author analyzes merger document details between AbbVie and Apogee, noting AbbVie's ultimatum and competitive interest in the AtD space, but does not state a personal position or forward call.
LOW
23:24
Jul 02
Jul 02
The tweet details the merger timeline between AbbVie and Apogee with no author position, noting that the atopic dermatitis space remains of interest to biopharma.
LOW
10:54
Jun 26
Jun 26
APGE co-mentioned as the relative valuation benchmark; acquired for $11B per parent context, author implies it is less attractive than KYMR on valuation.
MED
23:45
Jun 22
Jun 22
AbbVie acquires Apogee for $10.9B, highlighting value of experimental immunology drug zumilokibart.
LOW
12:13
Jun 22
Jun 22
Premarket movers show hyperscalers declining while chip stocks rise, with notable gains in Apogee Therapeutics on an AbbVie acquisition and Getty Images soaring on an OpenAI partnership.
11:53
Jun 22
Jun 22
The author declares OX40 target dead and questions SNY's Amlitelimab continuation, but provides no personal position or forward trade call.
LOW
11:52
Jun 22
Jun 22
US pre-market movers include Getty Images up 105% on an OpenAI display deal, Apple down 1% on device price pressures, and Apogee up 50% on an AbbVie acquisition agreement.
11:43
Jun 22
Jun 22
AbbVie announces agreement to acquire Apogee Therapeutics for 135 dollars 11 cents per share in cash to deepen its immunology pipeline.
11:25
Jun 22
Jun 22
AbbVie agreed to acquire Apogee Therapeutics for 10.9 billion dollars to strengthen its anti-inflammatory drug portfolio amid rising competition for its top-selling product.
11:00
Jun 22
Jun 22
Reports ABBV to acquire APGE for $135.11/share cash; no directional view from speaker.
MED
00:55
Jun 21
Jun 21
The tweet maps biotech M&A timing and independent name catalysts since the XBI bottom, but it is a factual research summary without explicit author positions or forward calls.
LOW
18:24
Jun 20
Jun 20
Buy APGE on competitive moat in extended half-life IL4/13 biologics — author (appears to be a medical professional/analyst) argues APGE leads competitors by over a year in this specific mechanism, a durable differentiation not present in IL23.
MED
16:20
Jun 20
Jun 20
The author argues that a buyout of APGE is unlikely due to big pharma's existing IL23 antibodies and JNJ's cheapness, making a deal improbable.
LOW
15:57
Jun 20
Jun 20
APGE mentioned as most advanced extended half-life IL4/13 past Phase 2b, subject to ABBV acquisition; author dislikes the deal but acknowledges drug advancement.
MED
23:40
Jun 19
Jun 19
Reports AbbVie's acquisition of Apogee Therapeutics valued near $11bn; M&A event with no directional view from speaker.
MED
20:12
Jun 19
Jun 19
AbbVie acquiring APGE at ~$11B (~3-4x peak AtD sales), cited as read-through catalyst for AtD space M&A valuation benchmarks.
MED
17:34
Jun 19
Jun 19
Author acknowledges the APGE deal math suggests a lower price than $150 and expresses a wait-and-see view on ABVX without taking a position.
LOW
14:52
Jun 19
Jun 19
The tweet suggests plane tracking alpha exists for AbbVie and Apogee, referencing a quoted context about unusual AbbVie fleet activity near Bozeman that previously preceded a major deal, but the author does not state a position or forward call.
LOW
14:47
Jun 19
Jun 19
Author congratulates Affinity on their portfolio acquisitions and highlights several biotech holdings as likely to bear more fruit, but does not state a personal position.
LOW
14:34
Jun 19
Jun 19
Author reviews merger documents and identifies read-through targets for potential takeovers, but does not state personal positions or forward calls.
LOW
14:28
Jun 19
Jun 19
Author expresses skepticism about a potential ABBV-APGE deal despite reporting a premium calculation, noting personal bearishness and congratulating longs without taking a position.
LOW
14:19
Jun 19
Jun 19
AbbVie's acquisition of biotech firm Apogee Therapeutics is expected to be announced as soon as Monday according to the Financial Times.
14:19
Jun 19
Jun 19
AbbVie is nearing an approximately 11 billion dollar deal to acquire biotech firm Apogee Therapeutics as reported by the Financial Times.
21:16
Jun 10
Jun 10
Short APGE — management is making demonstrably false claims (Dupixent generic having zero impact on a same-MoA IL4/13 launch, fabricated ISR discontinuation data vs. clinical trial evidence), suggesting promotional desperation to support a structurally challenged launch against a soon-to-be-generic blockbuster; author is a practicing physician with direct clinical experience contradicting management's narrative.
HIGH
12:13
Jun 10
Jun 10
Author speculates about potential acquisition targets for Sanofi but uses hedged language and does not state a personal position or directional view.
LOW
23:25
Jun 09
Jun 09
Author endorses buying APGE based on past success with NUVL but does not state a current position or forward conviction.
23:15
Jun 09
Jun 09
Author notes current prices of ABVX and APGE for posterity without expressing a directional view or position.
LOW
22:41
Jun 09
Jun 09
Short APGE as the author identifies three concurrent negative catalysts — OX40 black box safety signal, lead asset failure vs. SOC, and LLY's Ebgylss winning Q8W dosing approval on the same IL-13 epitope — eliminating the remaining bull cases while the stock remains severely overvalued.
HIGH
About APGE Analyst Coverage
Buzzberg tracks APGE (Apogee Therapeutics, Inc. Common Stock) across 8 sources. 1 bullish vs 7 bearish calls from 8 analysts. Sentiment: mixed to bearish. 54 total trade ideas tracked. Past 7 days: 1 watch. Latest voices: A May MD, seedy19tron, BarbarianCap.